FIL Ltd raised its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 27.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,101,883 shares of the biopharmaceutical company's stock after acquiring an additional 1,098,364 shares during the quarter. FIL Ltd owned about 0.25% of Bristol-Myers Squibb worth $288,563,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in BMY. United Bank lifted its stake in Bristol-Myers Squibb by 2.7% in the 3rd quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock worth $896,000 after purchasing an additional 456 shares in the last quarter. Morse Asset Management Inc lifted its position in Bristol-Myers Squibb by 25.0% during the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after purchasing an additional 2,000 shares during the last quarter. EP Wealth Advisors LLC grew its stake in Bristol-Myers Squibb by 25.0% in the 3rd quarter. EP Wealth Advisors LLC now owns 49,252 shares of the biopharmaceutical company's stock worth $2,548,000 after buying an additional 9,836 shares in the last quarter. Dunhill Financial LLC increased its holdings in shares of Bristol-Myers Squibb by 39.8% in the 3rd quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 189 shares during the last quarter. Finally, MML Investors Services LLC increased its stake in Bristol-Myers Squibb by 1.5% in the third quarter. MML Investors Services LLC now owns 313,688 shares of the biopharmaceutical company's stock valued at $16,230,000 after acquiring an additional 4,554 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.
Insider Transactions at Bristol-Myers Squibb
In related news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction on Friday, February 14th. The shares were acquired at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the purchase, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.09% of the company's stock.
Bristol-Myers Squibb Stock Up 0.4 %
Bristol-Myers Squibb stock traded up $0.22 on Friday, hitting $50.68. 13,408,290 shares of the stock traded hands, compared to its average volume of 12,926,949. The business's fifty day simple moving average is $57.71 and its 200 day simple moving average is $56.78. The firm has a market cap of $103.11 billion, a P/E ratio of -11.46, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33.
Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.
Bristol-Myers Squibb Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 4.89%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -56.11%.
Analyst Ratings Changes
BMY has been the subject of a number of recent research reports. Cantor Fitzgerald boosted their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Truist Financial lifted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Finally, Citigroup raised their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus price target of $57.67.
Check Out Our Latest Report on Bristol-Myers Squibb
About Bristol-Myers Squibb
(
Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Articles
Before you consider Bristol-Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.
While Bristol-Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
